Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In NASH, Gilead Swung For The Fences And Struck Out Again

Executive Summary

Gilead took a risky approach with selonsertib in NASH, pursuing a tough liver fibrosis benefit and failing, continuing a trend of disappointments outside of its antiviral franchises. Analysts don’t expect the second Phase III study in less-sick patients to succeed either.


Related Content

Conatus Endures Another NASH Setback With Failure To Hit Fibrosis Endpoint
Intercept Retakes The Lead In NASH
Science Matters: Merck Joins Crowded NASH Race As Several Data Readouts Loom
Gilead Hit With Another NASH Setback As Selonsertib Fails In First Phase III
Madrigal Cements Case For Hepatic Fat Reduction, Other NASH Benefits With MGL-3196
Viking’s Liver Fat Reduction Data Portend A New Competitor In NASH
Sierra Believes It Can Do Better Than Gilead With JAK Inhibitor Momelotinib
New Data Cast Doubt On Gilead's Phase III NASH Candidate Selonsertib
Another Simtuzumab Failure For Gilead


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts